Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL

3 luglio 2026 aggiornato da: Xin Cheng, Huashan Hospital

Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL: A Single-Center, Prospective, Single-Arm, Self-Controlled Clinical Trial.

This study is a single-center, prospective, single-arm, self-controlled clinical trial designed to assess the safety and efficacy of edaravone dexborneol sublingual tablets for blood-brain barrier (BBB) dysfunction in patients with CADASIL.

The study will enroll approximately 60 participants aged 18 to 80 years with genetically confirmed CADASIL. Participants will be followed for a total duration of 12 months, including two consecutive phases.

  • Phase 1 is a 6-month natural history observation period, during which participants do not receive the study drug and continue their routine standard care for CADASIL.
  • Phase 2 is a 6-month drug intervention period, in which participants will receive edaravone dexborneol sublingual tablets to investigate the effect on the BBB water exchange rate (kw), measured by diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) MRI, and to assess potential benefits on stroke risk reduction, cognitive function, and gait performance.

The primary endpoint is the change in kw measured by DP-pCASL. Secondary endpoints include the incidence of clinical stroke events; changes in neuropsychological performance, MRI-based CSVD biomarkers, gait and motor assessments, functional disability and activities-of-daily-living scales, and peripheral blood biomarkers. Safety assessments will include adverse events (AEs) and serious adverse events (SAEs).

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study is a single-center, prospective, single-arm, self-controlled clinical trial evaluating the safety and efficacy of edaravone dexborneol sublingual tablets for blood-brain barrier (BBB) dysfunction in CADASIL patients.

  1. Background and Rationale CADASIL is the most common monogenic form of cerebral small vessel disease (CSVD), caused by pathogenic mutations in the NOTCH3 gene. BBB dysfunction is increasingly recognized as one of the core pathophysiological mechanisms in CADASIL, contributing to white matter injury, progressive cognitive decline, and recurrent stroke, and represents a potential therapeutic target. Edaravone Dexborneol, a novel free radical scavenger and anti-inflammatory agent, has shown neuroprotective effects in preclinical models and clinical trials for ischemic stroke. The TASTE-SL trial demonstrated that edaravone dexborneol improved 90-day functional outcomes in patients with acute ischemic stroke. Based on these findings, this study is designed to systematically assess the efficacy and safety of edaravone dexborneol sublingual tablets in ameliorating BBB dysfunction in patients with CADASIL, and to investigate their potential benefits in reducing stroke risk and improving cognitive function.
  2. Study Design and Methods A total of 60 participants aged 18 to 80 years with genetically confirmed CADASIL will be recruited. The primary endpoint is the change in the BBB water-exchange rate (kw), measured by diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) MRI. The trial consists of two sequential phases: during the first 6 months (natural disease observation period), participants do not receive the study drug and continue their routine standard care for CADASIL, allowing for the characterization of intra-individual natural variability of kw. During the subsequent 6 months (treatment period), all participants will receive edaravone dexborneol sublingual tablets in addition to their routine standard care, and treatment-related changes in kw will be evaluated. All participants will undergo multimodal MRI scanning at baseline, month 6, and month 12, along with comprehensive assessments including cognitive testing, clinical scales, and peripheral blood biomarkers.
  3. Significance This study is expected to fill a significant gap in pharmacological intervention research for CADASIL and provide clinical evidence supporting the potential extension of edaravone dexborneol to genetically mediated small vessel disease.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Cina
      • Shanghai, Cina
        • Huashan Hospital, Fudan University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • 1. Genetically Confirmed CADASIL: Diagnosis of CADASIL confirmed by NOTCH3 genetic testing.
  • 2. Age: Between 18 and 80 years.
  • 3. Lacunar Lesion Requirement: Presence of ≥1 lacune on brain MRI.
  • 4. No acute ischemic stroke or intracerebral hemorrhage within the past 3 months.
  • 5. Modified Rankin Scale (mRS) score of 0 to 3.
  • 6. Contraception Requirements: Women of childbearing potential and male participants with female partners of childbearing potential must agree to use effective contraception during the study and 30 days after the last dose of the investigational drug.Female participants must have a negative pregnancy test before enrollment.
  • 7. Informed Consent: Participants or their legal representatives must voluntarily sign an informed consent form (ICF).

Exclusion Criteria:

  • 1. Presence of other major neurological disorders: Non-vascular white matter diseases (e.g., multiple sclerosis, carbon monoxide encephalopathy), central nervous system infections, Creutzfeldt-Jakob disease, primary Parkinson's disease, traumatic brain injury, or intracranial tumors.
  • 2. Severe Liver Dysfunction: Active liver disease (acute hepatitis, chronic active hepatitis, cirrhosis) or ALT/AST >2× ULN.
  • 3. Severe renal impairment (serum creatinine >1.5× ULN).
  • 4. Life Expectancy <1 year due to severe systemic diseases.
  • 5. Contraindications to MRI: Participants with MRI-incompatible implants, severe claustrophobia, or inability to undergo MRI.
  • 6. Known Allergies: History of hypersensitivity to Dexborneol, natural borneol, edaravone, or any excipients (e.g., mannitol, copovidone, microcrystalline cellulose, silica, magnesium stearate).
  • 7. Pregnancy and Lactation: Pregnant or lactating women, or those planning pregnancy during the study period.
  • 8. Participation in Other Clinical Trials
  • 9. Other Investigator-Determined Factors: Any other medical, psychological, or social condition that, in the investigator's judgment, makes the patient unsuitable for participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Edaravone Dexborneol Sublingual Tablets
All enrolled participants follow a two-phase, self-controlled schedule. During the first 6 months (natural history observation period), participants do not receive the study drug and continue their routine standard care for CADASIL. During the subsequent 6 months (treatment period), participants receive edaravone dexborneol sublingual tablet in addition to their routine standard care.
Droga: Edaravone Dexborneol Sublingual Tablets
One tablet (containing edaravone 30 mg and dexborneol 6 mg) is taken sublingually twice daily for the 6-month treatment period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in whole-brain blood-brain barrier water exchange rate (kw) measured by DP-pCASL MRI
Lasso di tempo: Baseline, Month 6, and Month 12
The blood-brain barrier (BBB) water exchange rate (kw), an imaging marker of BBB function, is quantified on whole-brain diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) MRI at baseline, month 6, and month 12. All participants are untreated during the first 6 months (observation period) and receive edaravone dexborneol sublingual tablets during the subsequent 6 months (treatment period). The change in kw during the observation period (baseline to Month 6) is compared with the change during the treatment period (Month 6 to Month 12) to distinguish the natural trajectory of BBB dysfunction from a potential treatment effect.
Baseline, Month 6, and Month 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinical Stroke Events
Lasso di tempo: 12 months
Number and proportion of participants experiencing any stroke event, including ischemic stroke and hemorrhagic stroke, recorded throughout the study.
12 months
Change in Montreal Cognitive Assessment (MoCA) Score
Lasso di tempo: Baseline, Month 6, and Month 12
The Montreal Cognitive Assessment (MoCA) is a cognitive screening tool that assesses multiple domains, including attention, concentration, executive function, memory, language, visuospatial skills, abstract thinking, calculation, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive function.
Baseline, Month 6, and Month 12
Change in Auditory Verbal Learning Test (AVLT) Score
Lasso di tempo: Baseline, Month 6, and Month 12
Verbal episodic memory is assessed using the Huashan version of the Auditory Verbal Learning Test (AVLT-H). The test uses a list of 12 words from three semantic categories (4 words per category). The examiner reads the list aloud and the participant recalls the words immediately; this is repeated for three consecutive trials. The immediate recall score is the sum of correctly recalled words across the three trials, ranging from 0 to 36, with higher scores indicating better memory function.
Baseline, Month 6, and Month 12
Change in Boston Naming Test Score
Lasso di tempo: Baseline, Month 6, and Month 12
The Boston Naming Test (BNT) is a widely used neuropsychological assessment that measures confrontation naming-the ability to retrieve and produce the correct name for a visually presented object. Boston Naming Test includes 30 items and evaluates language through measuring the total of correct responses. The minimum score is 0, and the maximum score is 30. Higher score indicates better language.
Baseline, Month 6, and Month 12
Change in Stroop Color-Word Test completion time
Lasso di tempo: Baseline, Month 6, and Month 12
Inhibitory function and executive control are assessed using the Stroop Color-Word Test. In the color-word interference condition, participants name the ink color of color words while inhibiting the automatic tendency to read the word. The outcome is the completion time in seconds; shorter times indicate better executive function.
Baseline, Month 6, and Month 12
Change in Stroop Color-Word Test number of correct responses
Lasso di tempo: Baseline, Month 6, and Month 12
Inhibitory function and executive control are assessed using the Stroop Color-Word Test. In the color-word interference condition, participants name the ink color of color words while inhibiting the automatic tendency to read the word. The outcome is the number of correct responses, ranging from 0 to 50, with higher scores indicating better executive function.
Baseline, Month 6, and Month 12
Change in Symbol Digit Modalities Test (SDMT) Score
Lasso di tempo: Baseline, Month 6, and Month 12
The total number of correct symbol-digit pairings completed within 90 seconds (common score range: 0-105), where a higher score indicates better processing speed, sustained attention, and visual scanning.
Baseline, Month 6, and Month 12
Change in Trail Making Test (TMT) Score
Lasso di tempo: Baseline, Month 6, and Month 12
The Trail Making Test (TMT) is a widely used neuropsychological test that measures processing speed, visual attention, sequencing, mental flexibility, and executive function. The score is the time it takes to complete the task. Lower times are better, while longer times indicate greater impairment.
Baseline, Month 6, and Month 12
Change in Digit Span Test (DST) Score
Lasso di tempo: Baseline, Month 6, and Month 12
Digit Span Test (DST) consists of forward and backward subtests, that respectively assess attention and executive function through measuring the number of correct digit sequences. The minimum score is 0 , and the maximum scores are respectively 10 and 9 for forward and backward subtests. The total score is the sum of the forward and backward subtests, ranging from 0 to 19, with higher scores indicating better attention and working memory.
Baseline, Month 6, and Month 12
Change in Hamilton Anxiety Rating Scale (HAMA) score
Lasso di tempo: Baseline, Month 6, and Month 12
The Hamilton Anxiety Rating Scale (HAMA) is a clinician-administered scale used to assess the severity of anxiety symptoms. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety symptoms.
Baseline, Month 6, and Month 12
Change in Hamilton Depression Rating Scale (HAMD) score
Lasso di tempo: Baseline, Month 6, and Month 12
The Hamilton Depression Rating Scale (HAMD) is a widely used clinical tool for assessing the severity of depression. It consists of multiple items that evaluate various aspects of depressive symptoms, including mood, guilt, suicidal ideation, work and interest, among others. It is scored on a scale from 0 to 52, with higher scores indicating more severe symptoms.
Baseline, Month 6, and Month 12
Change in number of lacunes
Lasso di tempo: Baseline, Month 6, and Month 12
The change in the number of lacunes on brain MRI, assessed using T1-weighted, T2-weighted, and FLAIR sequences. Lacunes are markers of cerebral small vessel disease; an increased number may indicate progression of vascular pathology.
Baseline, Month 6, and Month 12
Change in Number of Microbleeds
Lasso di tempo: Baseline, Month 6, and Month 12
The change in the number of cerebral microbleeds on brain MRI, assessed using susceptibility-weighted imaging (SWI) or T2*-weighted gradient-echo imaging. Cerebral microbleeds are markers of cerebral small vessel disease; an increased burden may indicate worsening vascular pathology.
Baseline, Month 6, and Month 12
Change in White Matter Hyperintensity Volume
Lasso di tempo: Baseline, Month 6, and Month 12
The change in white matter hyperintensity (WMH) volume, assessed using quantitative MRI analysis and reported in milliliters (mL). This measure evaluates the impact of treatment on the progression of cerebral small vessel disease. A smaller increase or a decrease in WMH volume suggests a treatment benefit.
Baseline, Month 6, and Month 12
Change in perivascular space (PVS) score
Lasso di tempo: Baseline, Month 6, and Month 12
The change in the burden of enlarged perivascular spaces on brain MRI, rated on a validated visual rating scale (0 to 4) in the basal ganglia and centrum semiovale. Enlarged perivascular spaces are markers of cerebral small vessel disease; a higher score may indicate worsening vascular pathology.
Baseline, Month 6, and Month 12
Change in total brain volume
Lasso di tempo: Baseline, Month 6, and Month 12
The change in total brain volume on brain MRI, assessed using quantitative volumetric analysis of 3D T1-weighted images and reported in milliliters (mL). Loss of brain volume reflects atrophy associated with cerebral small vessel disease; a greater reduction in brain volume may indicate disease progression.
Baseline, Month 6, and Month 12
Change in fractional anisotropy (FA)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in fractional anisotropy (FA) derived from diffusion tensor imaging (DTI), an index of white matter microstructural integrity. A decrease in FA reflects loss of white matter integrity and may indicate progression of cerebral small vessel disease.
Baseline, Month 6, and Month 12
Change in mean diffusivity (MD)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in mean diffusivity (MD) derived from diffusion tensor imaging (DTI). An increase in MD reflects loss of white matter microstructural integrity and may indicate progression of cerebral small vessel disease.
Baseline, Month 6, and Month 12
Change in peak width of skeletonized mean diffusivity (PSMD)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in peak width of skeletonized mean diffusivity (PSMD) derived from diffusion tensor imaging (DTI), a fully automated marker of cerebral small vessel disease. An increase in PSMD may indicate worsening white matter damage and disease progression.
Baseline, Month 6, and Month 12
Change in Tinetti Balance and Gait Assessment score
Lasso di tempo: Baseline, Month 6, and Month 12
Assessed using the Tinetti Balance and Gait Evaluation. The scale consists of a balance section (9 items, max 16 points) and a gait section (7 items, max 12 points). Total scores range from 0 to 28, with higher scores indicating better balance and gait, and lower fall risk.
Baseline, Month 6, and Month 12
Changes in Short Physical Performance Battery (SPPB) score
Lasso di tempo: Baseline, Month 6, and Month 12
Changes in Short Physical Performance Battery (SPPB) score (range 0-12, with higher score indicating better physical performance).
Baseline, Month 6, and Month 12
Change in modified Rankin Scale (mRS) score
Lasso di tempo: Baseline, Month 6, and Month 12
The change in modified Rankin Scale (mRS) score. The mRS is a widely used functional outcome measure that assesses the degree of disability or dependence in daily activities. The scale ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. An increase in mRS score suggests a worsening of functional status.
Baseline, Month 6, and Month 12
Change in Instrumental Activities of Daily Living (IADL) scale score
Lasso di tempo: Baseline, Month 6, and Month 12
The change in Lawton-Brody Instrumental Activities of Daily Living (IADL) scale score. IADLs are activities that support daily life and involve interacting with one's environment, such as managing finances, medication and health, shopping, meal preparation, housekeeping, laundry, communication, and community mobility. The scale is scored from 0 to 8, with higher scores indicating greater functional independence.
Baseline, Month 6, and Month 12
Change in serum neurofilament light chain (NfL)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum neurofilament light chain (NfL) concentration. NfL is a biomarker of neuroaxonal injury; higher levels may indicate greater neuronal damage.
Baseline, Month 6, and Month 12
Change in serum high-sensitivity C-reactive protein (hs-CRP)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum high-sensitivity C-reactive protein (hs-CRP) concentration. hs-CRP is a marker of systemic inflammation; higher levels may indicate a greater inflammatory burden.
Baseline, Month 6, and Month 12
Change in serum interleukin-6 (IL-6)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum interleukin-6 (IL-6) concentration. IL-6 is a pro-inflammatory cytokine; higher levels may indicate a greater inflammatory burden.
Baseline, Month 6, and Month 12
Change in serum interleukin-8 (IL-8)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum interleukin-8 (IL-8) concentration. IL-8 is a pro-inflammatory chemokine; higher levels may indicate a greater inflammatory burden.
Baseline, Month 6, and Month 12
Change in serum interleukin-10 (IL-10)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum interleukin-10 (IL-10) concentration. IL-10 is an anti-inflammatory cytokine; higher levels reflect an anti-inflammatory response.
Baseline, Month 6, and Month 12
Change in serum tumor necrosis factor-alpha (TNF-α)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum tumor necrosis factor-alpha (TNF-α) concentration. TNF-α is a pro-inflammatory cytokine; higher levels may indicate a greater inflammatory burden.
Baseline, Month 6, and Month 12
Change in serum glial fibrillary acidic protein (GFAP)
Lasso di tempo: Baseline, Month 6, and Month 12
The change in serum glial fibrillary acidic protein (GFAP) concentration. GFAP is a biomarker of astroglial activation and injury; higher levels may indicate greater astrocytic damage.
Baseline, Month 6, and Month 12
Adverse events
Lasso di tempo: 12 months
Adverse events, confirmed by the Clinical Event Committee.
12 months
Serious adverse events
Lasso di tempo: 12 months
Serious adverse events, confirmed by the Clinical Event Committee.
12 months
Liver function impairment
Lasso di tempo: 12 months
Number of participants with Alanine Aminotransferase level >2.0×upper limit of the normal
12 months
Renal function impairment
Lasso di tempo: 12 months
Number of participants with serum creatinine >1.5×upper limit of the normal.
12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Huashan Hospital

Collaboratori

Jiangsu Simcere Pharmaceutical Co., Ltd.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

29 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 luglio 2026

Primo Inserito (Effettivo)

9 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • KY2026-703

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su CADASILE

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Dominican Republic

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi